The drug is a loose and porous mass of white color, hygroscopic.
Pharmacotherapeutic group: immunostimulative drug.
ATC code: L03AB03
INGARON® is a recombinant human interferon gamma consisting of 144 aminoacid residues (a. r.), being deprived of the first three a.r. Cys-Tyr-Cys, replaced by Met. The molecular weight is 16.9 kDa. It is produced by means of microbiological synthesis in recombinant Escherichia coli strain and purified by column chromatography. Specific antiviral activity on human fibroblast cells infected with vesicular stomatitis virus, is 2∙107 units per mg of protein.
Interferon gamma (immune interferon) is the most important proinflammatory cytokine produced by CD4 Th1 cells and CD8 cytotoxic suppressor cells being natural killer cells in a human body. Interferon gamma receptors are present in macrophages, neutrophils, natural killer cells, and cytotoxic T-lymphocytes. The drug activates effector functions of these cells, in particular, their microbicide activity, cytotoxicity, their production of cytokines, superoxide and nitroxide radicals (thus causing death of intracellular parasites). Interferon gamma blocks viral DNA and RNA replication, viral proteins synthesis and mature viral particles assembly. Upon that, it causes a cytotoxic effect on virus-infected cells.
Interferon gamma inhibits В-cell response to interleukine-4, suppresses the production of IgE and expression of CD23-antigen. It induces the apoptosis of differentiated B-cells giving rise to autoreactive clones. Interferon gamma cancels the suppressive effect of interleukine-4 on interleukine-2-dependant proliferation and generation of lymphokine-activated killers. It activates the production of acute inflammation phase proteins, intensifies the expression of С2 and С4 gens of complement system components.
Unlike other interferons, interferon gamma increases the expression of major histocompatibility complex antigens of both Ist and IInd class on different cells, upon that, it induces the expression of these molecules even upon cells, which do not express them constitutively. Thus, the efficiency of antigens presentation and their recognition by Т- lymphocytes improves.
Interferon gamma blocks the synthesis of β-TGF being responsible for the development of pulmonary and hepatic fibrosis.
(in combined therapy) of influenza.
Idiosyncrasy to interferon gamma or any other component of the drug. Pregnancy. Pediatric use (under 7 years of age).
Posology and Administration
Intranasal. The contents of the vial are dissolved in 5 ml of water for injection.
At the first signs of influenza or ARVI, apply 2 drops into each nasal passage 5 times a day for 5-7 days, the drug is to be used after cleaning nasal passages.
For influenza and ARVI prevention upon contacting an infected person and/or upon exposure to cold, apply 2-3 drops into each nasal passage every other day for 10 days. If necessary, preventive courses can be repeated. Upon single exposure, one application is sufficient.
For the purpose of even distribution of the drug in the nasal cavity, a few minutes of finger-massage of nose alae is recommended after application.
No side effects known.
Lyophilisate for intranasal solution in vials of 100 000 IU/vial. Vials are packed 1, 5 pieces into cartons.
Store in a dry place, protected from light and out of the reach of children, at a maximum temperature of +25 ºС.
Store the drug solution in a fridge for 10 days maximum (protect from freezing).
2 years. Do not use beyond the expiration date.
Available over the counter.
“Research and Production Enterprise “Pharmaclon” LLC, Russia.
42200, Moscow Region, Serpukhov city,
Chekhov str., 30/34